Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial

INTRODUCTION: BAY 81‐8973 (Kovaltry(®)) is a full‐length, unmodified recombinant human factor VIII approved in China for prophylaxis and on‐demand treatment in patients with haemophilia A. Limited access to FVIII prophylaxis in China has historically led to this population being undertreated. This s...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haemophilia
Auteurs principaux: Yang, Renchi, Sun, Jing, Zhao, Yongqiang, Wang, Xuefeng, Wu, Depei, Tseneklidou‐Stoeter, Despina, Wu, Junde, Church, Nikki
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
ORIGINAL ARTICLES
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6850381/
https://ncbi.nlm.nih.gov/pubmed/30993836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13751
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires